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Introduction

Signs & Symptoms

References
inhibitor–induced angioedema, whereas
antihistamines and corticosteroids do
not target the underlying mechanism
(Scalese & Reinaker, 2016, p. 874).

ACE inhibitors are associated with a variety of signs and symptoms. The following, but
not limited too, are some of them. The most common symptom is a cough. The patients
should notify the health care provider immediately because they may be experiencing a
potential reaction to the medication. According to Wadelius et al., (2014), the following
are possible risk factors and side effects (p. 479).

Angiotensin-converting enzyme
inhibitor (ACEI) medications are one of
the leading causes of angioedema in the
United States, also known as ACEI-RA
(Chan & Soliman, 2015, p. 207). ACE
inhibitors are among the most
commonly prescribed medications
worldwide because they are indicated
for the management of hypertension,
congestive heart failure, myocardial
infarction, diabetic nephropathy, and
chronic kidney disease (Chan & Soliman,
2015, p. 207). According to Spencer
(2016), there are an estimated 40
million people taking ACE inhibitors for
either hypertension or congestive heart
failure (CHF). Angioedema is estimated
to occur in 0.1%-0.7% of patients on
ACE inhibitor therapy. Of those who
present to the emergency department
with angioedema, 35% of cases are
attributed to ACEI. Additionally, one
study concluded that African-Americans
are three times more likely to develop
ACEI-RA within six months of starting
ACE inhibitor therapy (Spencer, 2016).
0.7% may seem like a small number, but
that is about twenty-eight thousand
patients a year. There are several risk
factors for developing ACE inhibitor
angioedema. The primary risk factor is
being African-American. The female
population, with a history of
angioedema and chronic disease are all
contributing factors. What may seem
odd is that it does not matter how long
a patient is taking the medication
before they develop a reaction. Some
(Wadelius et al., 2014, p. 479)
patients have taken the medication for
more than 20 years before they had a
reaction. Understanding Angioconverting enzyme inhibitors are
important for all parties involved. As a
healthcare provider who is going to be
writing prescriptions, it is paramount to
know the patients’ health background
and how ACEI works on a cellular level.
Only after obtaining all the correct
information will the healthcare provider
choose whether this medication is right
for the patient. Do the risks outweigh
the benefits or vice versa?
("Picture," n.d.)

Implications for
Nursing Care

(RAAS, 2006)

Underlying
Pathophysiology
Angioedema is a potentially lifethreatening adverse effect of ACE
inhibitors, with a reported incidence of 0.1
to 6%. ACE-inhibitor–related angioedema is
asymmetric, nonpitting, nontender edema
that can appear anywhere on the body but
commonly affects the head and neck area
(Chan & Soliman, 2015 (p. 207). According
to Chan and Soliman (2015), ACEI-RA is not
considered a true allergic reaction but is
considered an adverse class effect
secondary to the mechanism of action (p.
207). A true allergic reaction would involve
IgE antibodies. Interestingly, ACEI-RA is not
IgE mediated; the physiology of the
condition is caused by the levels of the
blood vessel-dilating peptide bradykinin in
the body (Spencer, 2016). Bradykinin
counterbalances the vasoconstrictive
workings of the renin-angiotensinaldosterone system and is thought to be a
primary mediator in nonallergic
angioedemas (Spencer, 2016). ACE
inhibitors, medications with a –pril suffix
(e.g., captopril, lisinopril [Prinivil®],

fosinopril [Monopril®]), lower blood pressure
by inhibiting the action of angiotensinconverting enzyme, thus interrupting the
conversion of angiotensin I to angiotensin II (a
potent vasodilator) and aldosterone (Wilson
et al., 2014; Wynn & Maxey, 2012). ACE
inhibitors also prevent the breakdown of the
enzyme bradykinin (Felicilda-Reynaldo &
Kenneally, 2015, p. 180). Bradykinin in low
doses causes vasodilation, which potentiates
the action of ACE inhibitors to lower blood
pressure (Felicilda-Reynaldo & Kenneally,
2015, p. 180).

Significance of
Pathophysiology
Understanding how the
pathophysiology of Angiotensinconverting enzyme inhibitor (ACEI) is
essential in deciding if this medication is
correct to resolve the patient’s
hypertension. This medication can lead to
severe swelling, possible intubation or
even tracheostomy placement. Patients
with allergic emergencies presenting to
an ED often receive medications including
epinephrine,

antihistamines, and corticosteroids.
Because ACEI angioedema is not mediated
by mast cell degranulation, the efficacy of
these medications remains controversial
(Winter, Rosenbaum, Vilke, & Almazroua,
2013, p. 777). According to Scalese &
Reinaker (2016), a medication called
icatibant (Firazyr), which is administered
only once subcutaneously at a dose of
30mg, has proven to be extremely
successful in treating ACEI-RA. . How this
medication works is by blocking the
bradykinin at the B2 receptor site. By
doing this the vasodilation effects of
bradykinin are rendered ineffective, thus
decreasing the swelling. Icatibant works
within minutes of administration and can
prevent invasive procedures that
otherwise, may be needed to ensure an
effective airway (Scalese & Reinaker, 2016,
p. 876) The downside to this medication is
that it costs $10,000 to $12,000 per dose.
This author believes that there is no
amount of money you can put on
someone’s life. A night in the intensive
care unit will cost much more. Fresh frozen
plasma, C1 inhibitor, and icatibant appear
to be safe and effective options for
treating ACE

ACE inhibitor angioedema is a
relatively common side effect. These
side effects could be seen in all clinical
care settings. As the bedside nurse, it
is important to be able to recognize
the signs and symptoms of ACEI-Ra
quickly. As an Advanced Practicing
Provider, it will be imperative to know
these patients will not present like a
typical allergic reaction i.e. itching,
urticaria. These patients will not be
treated in the same allergic reaction
manner. Emergency room nurses need
to recognize these patients as
immediate life threats and should be
seen immediately.
Patients being seen outside of the
Emergency room will need to be taken
to the Emergency room by EMS.
Advanced practice nurses will need to
be aware of the risk factors involved in
prescribing an ACEI to their patients. If
the risk factors are too high, the
provider will need to consider an
alternate medication. The early
warning sign of a reaction is a chronic
cough. All patient will need to be
educated extensively about the signs
and symptoms of angioedema.
Written literature will be very helpful
for the patient to take home.

Conclusion
ACEIs are very effective in treating
chronic diseases. APPs must be vigilant
in screening their patients as well as
their family members (if possible)
before prescribing these medications.
Nurses and APPs will need to provide
educational material patients. The
health and wellness of each patient is
essential. This author wants to educate
the community on the signs and
symptoms of ACEI-RA as well as the
pathophysiology.
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